Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan
<p>Optimal management of multiple myeloma (MM) remains challenging, particularly among patients with transplant-ineligible newly diagnosed MM (TIE NDMM). Daratumumab + lenalidomide + dexamethasone (DRd) is approved in Japan for the treatment of TIE NDMM. A previously reported real-world, retro...
Сохранить в:
| Главный автор: | |
|---|---|
| Другие авторы: | , , , , |
| Опубликовано: |
2025
|
| Предметы: | |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|
| _version_ | 1849927621428641792 |
|---|---|
| author | Kazuhito Suzuki (22688384) |
| author2 | Miku Ito (22688387) Chika Sakai (5712761) Hiroaki Tsuchiya (2437369) David Bin-Chia Wu (7251623) Yosuke Koroki (12979839) |
| author2_role | author author author author author |
| author_facet | Kazuhito Suzuki (22688384) Miku Ito (22688387) Chika Sakai (5712761) Hiroaki Tsuchiya (2437369) David Bin-Chia Wu (7251623) Yosuke Koroki (12979839) |
| author_role | author |
| dc.creator.none.fl_str_mv | Kazuhito Suzuki (22688384) Miku Ito (22688387) Chika Sakai (5712761) Hiroaki Tsuchiya (2437369) David Bin-Chia Wu (7251623) Yosuke Koroki (12979839) |
| dc.date.none.fl_str_mv | 2025-11-26T09:40:08Z |
| dc.identifier.none.fl_str_mv | 10.6084/m9.figshare.30719789.v1 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/dataset/Correlation_between_duration_of_first-line_treatment_with_daratumumab_lenalidomide_and_dexamethasone_and_overall_survival_in_patients_with_transplant-ineligible_multiple_myeloma_in_Japan/30719789 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Medicine Pharmacology Biotechnology Immunology Cancer Science Policy Mental Health Daratumumab duration of treatment lenalidomide newly diagnosed multiple myeloma overall survival real-world evidence |
| dc.title.none.fl_str_mv | Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan |
| dc.type.none.fl_str_mv | Dataset info:eu-repo/semantics/publishedVersion dataset |
| description | <p>Optimal management of multiple myeloma (MM) remains challenging, particularly among patients with transplant-ineligible newly diagnosed MM (TIE NDMM). Daratumumab + lenalidomide + dexamethasone (DRd) is approved in Japan for the treatment of TIE NDMM. A previously reported real-world, retrospective study of claims from the Japanese Medical Data Vision (MDV) database reported that first-line (1 L) DRd may improve outcomes versus second-line or later treatment in patients with TIE NDMM.</p> <p>Data from this study underwent further analysis to investigate the correlation between 1 L DRd duration of treatment (DoT) and overall survival (OS). DoT and OS outcomes were also assessed in subgroups defined by age (<75, ≥75 to <80, ≥80 years) and Charlson Comorbidity Index (CCI; low [score 0], medium [1 or 2], high [3 or 4] or very high [≥5]).</p> <p>Of 35,581 patients in the MDV database with a diagnosis of MM between January 1, 2016 and October 31, 2023, 200 patients (median age 77 years, median time from MM diagnosis 16 days) were prescribed 1 L DRd and had baseline/demographic data available at the start of treatment. After a median follow-up of 12.8 months, 1 L DRd DoT (median 26.9 months) showed high-positive correlation with OS (not reached) using Pearson’s (<i>r</i> = 0.832), Spearman’s rank (<i>r<sub>s</sub></i>=0.777), Kendall’s Tau (<i>τ<sub>b</sub></i>=0.703), and Fleischer’s (Corr [DoT, OS] = 0.789) coefficients in the overall population, and moderate- or high-positive correlation with OS across age and CCI score subgroups.</p> <p>These findings suggest that 1 L DRd DoT is a potential predictor of OS when used in Japanese clinical practice.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_af1da76fc59f9331e70a85dc8ae19ebd |
| identifier_str_mv | 10.6084/m9.figshare.30719789.v1 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30719789 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in JapanKazuhito Suzuki (22688384)Miku Ito (22688387)Chika Sakai (5712761)Hiroaki Tsuchiya (2437369)David Bin-Chia Wu (7251623)Yosuke Koroki (12979839)MedicinePharmacologyBiotechnologyImmunologyCancerScience PolicyMental HealthDaratumumabduration of treatmentlenalidomidenewly diagnosed multiple myelomaoverall survivalreal-world evidence<p>Optimal management of multiple myeloma (MM) remains challenging, particularly among patients with transplant-ineligible newly diagnosed MM (TIE NDMM). Daratumumab + lenalidomide + dexamethasone (DRd) is approved in Japan for the treatment of TIE NDMM. A previously reported real-world, retrospective study of claims from the Japanese Medical Data Vision (MDV) database reported that first-line (1 L) DRd may improve outcomes versus second-line or later treatment in patients with TIE NDMM.</p> <p>Data from this study underwent further analysis to investigate the correlation between 1 L DRd duration of treatment (DoT) and overall survival (OS). DoT and OS outcomes were also assessed in subgroups defined by age (<75, ≥75 to <80, ≥80 years) and Charlson Comorbidity Index (CCI; low [score 0], medium [1 or 2], high [3 or 4] or very high [≥5]).</p> <p>Of 35,581 patients in the MDV database with a diagnosis of MM between January 1, 2016 and October 31, 2023, 200 patients (median age 77 years, median time from MM diagnosis 16 days) were prescribed 1 L DRd and had baseline/demographic data available at the start of treatment. After a median follow-up of 12.8 months, 1 L DRd DoT (median 26.9 months) showed high-positive correlation with OS (not reached) using Pearson’s (<i>r</i> = 0.832), Spearman’s rank (<i>r<sub>s</sub></i>=0.777), Kendall’s Tau (<i>τ<sub>b</sub></i>=0.703), and Fleischer’s (Corr [DoT, OS] = 0.789) coefficients in the overall population, and moderate- or high-positive correlation with OS across age and CCI score subgroups.</p> <p>These findings suggest that 1 L DRd DoT is a potential predictor of OS when used in Japanese clinical practice.</p>2025-11-26T09:40:08ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.6084/m9.figshare.30719789.v1https://figshare.com/articles/dataset/Correlation_between_duration_of_first-line_treatment_with_daratumumab_lenalidomide_and_dexamethasone_and_overall_survival_in_patients_with_transplant-ineligible_multiple_myeloma_in_Japan/30719789CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/307197892025-11-26T09:40:08Z |
| spellingShingle | Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan Kazuhito Suzuki (22688384) Medicine Pharmacology Biotechnology Immunology Cancer Science Policy Mental Health Daratumumab duration of treatment lenalidomide newly diagnosed multiple myeloma overall survival real-world evidence |
| status_str | publishedVersion |
| title | Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan |
| title_full | Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan |
| title_fullStr | Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan |
| title_full_unstemmed | Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan |
| title_short | Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan |
| title_sort | Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan |
| topic | Medicine Pharmacology Biotechnology Immunology Cancer Science Policy Mental Health Daratumumab duration of treatment lenalidomide newly diagnosed multiple myeloma overall survival real-world evidence |